Can GLP-1 Drugs Reduce Alcohol Cravings?
A small randomized trial offers an encouraging signal. It does not yet make semaglutide an established treatment for alcohol use disorder.
The short answer
Possibly—but the evidence is still early. A 2025 phase 2 randomized clinical trial found that low-dose semaglutide reduced laboratory alcohol consumption, drinks per drinking day, and weekly craving among 48 adults with alcohol use disorder. It did not reduce every measured drinking outcome.
That result is important because randomized evidence is stronger than anecdotes or database associations. It is still one small, short trial and cannot establish how well the effect holds across populations, doses, or longer treatment.
What the trial actually found
Participants received semaglutide or placebo for nine weeks. Compared with placebo, semaglutide reduced the amount consumed during a laboratory self-administration task. The study also reported reductions in drinks per drinking day and weekly alcohol craving. Average drinks per calendar day and the number of drinking days did not significantly change.
This mixed pattern is more useful than a simple “works” headline: some dimensions shifted while others did not. Larger trials are needed to determine clinical benefit and safety for people actively seeking alcohol treatment.
Why might appetite medication affect alcohol?
GLP-1 signaling is involved in more than digestion. Preclinical work has prompted researchers to study reward-related behavior, but a plausible mechanism is not proof of a treatment effect in people. Human trials remain the decisive step.
What this means now
Semaglutide is not currently an established treatment for alcohol use disorder. People should not start, stop, or change a GLP-1 medication to address drinking without qualified medical guidance. Anyone worried about alcohol use deserves access to evidence-based care now, rather than waiting for this research to mature.
Citations
- Hendershot et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder. JAMA Psychiatry (2025).
- ClinicalTrials.gov: Semaglutide Therapy for Alcohol Reduction (NCT05891587)